Cover:
Rome, Castel Sant’Angelo or Hadrian’s Tomb.
ENDORSEMENT

ERA-EDTA’s endorsement is for the promotion of education in general, therefore the specific content of the event is the responsibility of the organiser.

ENDORSEMENT REQUESTED
High Patronage of the President of the Republic

International Society of Nephrology
Italian Society of Nephrology
Italian Society of Artificial Nutrition
Italian Society of Cardiovascular Ultrasound System

SCIENTIFIC ADVISORS
Luca Di Lullo, Antonio Bellasi

PRESIDENTS
Claudio Ronco, Alberto Santoboni, Antonio De Pascalis

HONORARY PRESIDENT
Peter Mc Cullough

ORGANIZING SECRETARIAT
Fenicia Events & Communication
info@fenicia-events.eu
Cardiovascular and renal disease are closely linked through different mechanisms such as chronic inflammation, dyslipidemia, calcium-phosphorus metabolism abnormalities, or comorbid conditions such as arterial hypertension, coronary artery disease and diabetes which may affect the heart and the kidneys at the same or in different times. At the same time, different hereditary (such as Polycystic kidney disease) and/or rare (such as Fabry’s disease) diseases also may impair simultaneously renal and cardiovascular functions.

The fourth edition of the CardioNephrology meeting will review comorbidities and metabolic abnormalities from the cardiorenal syndrome to the metabolic consequences of chronic kidney and heart disease that occur as the glomerular filtration rate decreases and link kidney and cardiovascular diseases.

The key features of the CardioNephrology 2019 are represented by the scientific sessions dedicated to the close interactions between heart, kidney and lung together with nutritional aspects in cardio – renal patients. Heart failure will be discussed both in acute and chronic kidney disease patients. Lectures dedicated to imaging will underscore potentials and limits of available diagnostic tools. Young cardioneurologists will be also specifically involved in vasculitis – dedicated as far as in poster session.

CardioNephrology 2019 will also focus on specific educational courses dedicated to critical appraisal, interventional nephrology, electrocardiography and blood gas analysis.

The meeting is arranged on several scientific sessions (some of them joined with other eminent scientific societies) and selected plenary lectures with eminent national and international speakers.

Finally, Meeting will close with World Kidney Day 2019 with several activities directly linked to this special issue.

Enjoy CardioNephrology 2019 with us

Luca Di Lullo, Antonio Bellasi, Claudio Ronco, Antonio De Pascalis, Alberto Santoboni, Peter Mc Cullough
LEPTIS MAGNA 2-4 ROOM

Chairmen: A. De Pascalis (Lecce), A. Santoboni (Colleferro)

9.00 Coronary angiography and contrast-induced nephropathy risk
G.P. Talarico (Rome)

9.15 Folic acid and cardiovascular prevention
G. Cianciolo (Bologna)

9.30 Sleep disturbances in CKD diabetic patients
TBA

9.45 Fluid assessment in heart failure patients with chronic kidney disease: the role of telehealth and telemedicine
A. Martino (Rome)

10.00 Cardiorenal involvement in adrenocortical failure
A. Falorni (Perugia)

10.15 Left atrial appendage occlusion in end-stage renal disease patients: an alternative to oral anticoagulant approach
G. Patti (Rome)

10.35 Pain therapy in cardio-renal patients
TBA

10.50 Chronic inflammation in cardiorenal patients:
hepcidin-C-reactive protein and lactoferrin
L. Di Lullo (Colleferro)

11.05 Hypertonic solutions for peritoneal dialysis patients
V. Barbera (Colleferro)
11.25 Cardiorenal anemia management: the role of biosimilar erythropoiesis-stimulating agents (ESA)
   *TBA*

11.45 CKD, Cardiorenal syndrome and dyslipidemia: an unsolved puzzle
   *P. Terrosu (Sassari)*

12.05 Cardiovascular interventional proceedings in end-stage renal disease patients
   *A. Granatelli (Tivoli)*

12.20 Bioequivalence and bioavailability in cardiorenal patients’ treatment
   *TBA*

12.40 Cardio and renal update on new treatment’s perspectives in Fabry’s disease
   *F. Pieruzzi (Monza)*

**LEPTIS MAGNA 1 ROOM**

*No Translation Tool available for this Session*

9.00 ECG Educational Course
   Discussant: *A. De Pascalis (Lecce), R. Rivera (Desio)*

**TARRAGONA ROOM**

*No Translation Tool available for this Session*

9.00 EGA Educational Course
   Discussant: *M.T. Sciarrone Alibrandi (Monza), U. Tulli (Tivoli)*

**CESAREA ROOM**

*No Translation Tool available for this Session*

9.00 Interventional Nephrology Educational Course
   Discussant: *A. Granata (Agrigento), N. Pirozzi (Rome), M. Tozzi (Varese)*
9.00 Critical appraisal in cardionephrology  
_C. Torino, G. Tripepi_ (Reggio Calabria)

13.00 _Light Lunch_

**LEPTIS MAGNA 2-4 ROOM**

14.00 _OPENING PLENARY LECTURE_  
_The link between chronic inflammation and cardiovascular disease in CKD_  
P. Raggi (Edmonton - Canada)  
Introducing: _C. Ronco_ (Vicenza)

**LEPTIS MAGNA 2-4 ROOM**

**I SESSION**

**CARDIOVASCULAR RISK FACTORS IN CHRONIC KIDNEY DISEASE PATIENTS (CKD): NEW THERAPEUTIC APPROACHES**

Chairmen: _A. Granatelli_ (Tivoli), _P. Menè_ (Rome)

14.30 Cardiorenal anemia syndrome: what’s new?  
_F. Locatelli_ (Lecco)

15.00 Anti PCSK9 antibodies in dyslipidemic patients with CKD: from clinical trials to real world evidences  
_A. Zambon_ (Padova)

15.30 Xanthine oxidase inhibitors and novel uricosuric agents for uric acid-related cardionephropathy treatment  
_L. Di Lullo_ (Colleferro), _L. Gesualdo_ (Bari)
16.10 Chronic inflammation and cardiovascular risk: new treatment’s perspectives
TBA

16.30 Obesity, cardiovascular disease and CKD
F. Muratori (Como)

LEPTIS MAGNA 1

I SESSION
DIRECT ORAL ANTICOAGULANTS (DOACs)
AND CHRONIC KIDNEY DISEASE:
A THREE-STEPS FLOW-CHART
Chairmen: S. Caramiello (Rome), A. Mugnolo (Legnago)

FIRST STEP: Management

14.30 Fragile patients and anticoagulant therapy between guidelines and real life
L. Di Lullo (Colleferro)

14.45 Two dosages for the same drug: two sides of the same coin?
R. Pola (Rome)

15.00 Emergencies management in DOACs treated patients
D. Toni (Rome)

SECOND STEP: Appropriateness

15.15 DOACs prescriptive appropriateness in atrial fibrillation patients with CKD
L. De Luca (Tivoli)

15.30 DOACs therapy according to patients phenotypes: a matter of safety? Anything else?
M. Ciavolella (Frascati)
15.45 DOACs and advanced CKD stages
L. Di Lullo (Colleferro)

THIRD STEP: Complexity

16.00 Direct oral anticoagulant therapy in patients with active cancer: between atrial fibrillation and deep venous thromboembolism
I. Bisceglia (Rome)

16.15 Direct oral anticoagulant therapy once daily treatment and thromboembolic prophylaxis in CKD patients
S. Radicchia (Perugia)

16.30 Efficacy and safety profile of direct oral anticoagulant therapy in old and fragile patients
M. Ciaburri (Rome)

TARRAGONA ROOM

I SESSION
CARDIOVASCULAR FEATURES OF KIDNEY TRANSPLANT PATIENTS
Chairmen: G. Grandaliano (Foggia), G. Otranto (Colleferro)

14.30 Which cardiologic evaluation for kidney transplantation patients’ waiting list?
L. Potena (Bologna)

15.00 Cardiovascular ageing in transplant patients: immune response and immunosoppressive treatment roles
G. Stallone (Foggia)

15.30 Cardiovascular involvement in transplant patients: how to manage?
E. Paoletti (Genoa)
Optimal timing of HCV-related hepatic disease treatment in kidney transplant recipients
G. Taliani (Rome)

Discussion

Coffee Break

LEPTIS MAGNA 2-4 ROOM

II SESSION
INTEGRATED MEDICINE AND CARDIONEPHROLOGY
Chairmen: S. Castellino (Taormina), A. Gorini (Rome)

Immune system involvement in cardiorenal diseases
M. Del Prete (Milan)

Herbal extracts as metabolic interferences: potential clinical uses
G. Occhionero (Isernia)

Biophysical integrated approach on cardionephrolgy: an emerging clinical perspective
A. Foletti (Lugano - Switzerland)

Stem cells as treatment option in cardiac diseases: available results
C. Castellitto (Bologna)

Discussion
LEPTIS MAGNA ROOM

II SESSION
LUNG, KIDNEY AND HEART AXIS
Chairmen: L. Di Lullo (Colleferro), C. Ronco (Vicenza)

17.00 Kidney, heart and lung: three sides of the same picture
Z. Ricci (Rome)

17.15 Chronic obstructive lung disease, right heart failure and kidney
disease
S. Di Simone (Colleferro)

17.30 New anti-cholinergic agents for chronic obstructive lung
disease: safety profile in cardiorenal patients
TBA

17.45 Primary and secondary pulmonary hypertension in CKD
M.P. Cicini (Rome)

18.00 Discussion

TARRAGONA ROOM

II SESSION
17.00 QUESTIONS’ CLINIC WITH THE EXPERTS:
CARDIORENAI SYNDROME
Chairmen: J. Kellum (Philadelphia - USA), C. Ronco (Vicenza)
LEPTIS MAGNA 2-4 ROOM

**III SESSION**

**CLINICAL HISTORY OF CARDIO-RENAL SYNDROME**
Chairmen: *A. De Pascalis* (Lecce), *R. Rivera* (Desio)

**18.15** Post-AKI kidney functional recovery  
*J. Kellum* (Pittsburgh - USA)

**18.30** Progression of kidney disease: from AKI to CKD  
*G. Grandaliano* (Foggia)

**18.45** Sepsis-related kidney damage  
*V. Cantaluppi* (Novara)

**19.00** The role of renal functional reserve  
*C. Ronco* (Vicenza)

**19.15** Discussion

LEPTIS MAGNA 1 ROOM

**III SESSION**

**CARDIAC ARRHYTHMIAS AND CHRONIC KIDNEY DISEASE**
Chairmen: *M. Mennuni* (Colleferro), *M. Rebecchi* (Rome)

**18.15** Pathophysiology of arrhythmias in CKD patients  
*D. Grigco* (Rome)

**18.30** Heart rhythm impairment: the silent killer  
*S. Mennuni* (Rome)

**18.45** Atrial fibrillation: prevention and treatment in renal replacement treatment’s patients  
*A. Politano* (Rome)
19.00  Atrial fibrillation: anticoagulation and hemodialysis
        M. Sgueglia (Rome)

19.15  Discussion

TARRAGONA ROOM

III SESSION
FUNCTIONAL FOODS AND NUTRACEUTICS IN CARDIORENAL PATIENTS
Chairmen: V. Barbera (Colleferro), F. Santoboni (Rome)

18.15  Pharmacological interactions and the treatment of dyslipidemia: how and when to treat
        R. Volpe (Rome)

18.30  Nutraceuticals and dyslipidemia management in cardiorenal patients
        C. Morozzi (Rome)

18.45  Hypercholesterolemia targets in high risk cardiorenal patients: beyond the statins
        V. Barbera (Colleferro)

19.00  Iron deficiency and anemia in CKD patients: new therapeutic approaches
        N. Marchitto (Terracina)

19.15  Prevention and treatment of nephrolithiasis
        TBA

LEPTIS MAGNA 2-4 ROOM

19.30  OPENING CERIMONY

AUTHORITIES’ GREETINGS

20.00  Closing
IV SESSION
ARTERIAL HYPERTENSION
Chairmen: A. Balducci (Rome), G. Reboldi (Perugia)

8.30 ESC/ESH and ACC guidelines: what’s new? What’s different?
F. Mallamaci (Reggio Calabria)

8.45 Anti-hypertensive treatment and nephro-protection?
Which target to achieve?
R. Pontremoli (Genoa)

9.00 Arterial hypertension in hemodialysis patients: how to treat?
And which target values to achieve?
L. De Nicola (Naples)

9.15 Resistant hypertension and cardiorenal risk: bad compliance or poor efficacy?
F. Viazzi (Genoa)

9.30 Potential new targets for antihypertensive therapy
K. Narkiewicz (Gdansk - Poland)

9.45 Discussion

10.00 PLENARY LECTURE
Management of chronic ischemic disease in CKD patients
G. Ferraiuolo (Rome)
Introducing: A. Santoboni (Colleferro)
IV SESSION
FABRY’S DISEASE
Chairmen: S. Feriozzi (Viterbo), F. Graziani (Rome)

8.30 Natural history of Fabry’s disease
F. Flocari (Civitavecchia)

8.45 Fabry’s disease: from glomerular hyperfiltration to overt CKD
A. Pisani (Naples)

9.00 Fabry’s disease: from arterial hypertension to hypertrophic cardiomyopathy
C. Autore (Rome)

9.15 Neurologic involvement in Fabry’s disease
G. Silvestri (Rome)

9.30 Fabry’s disease progression and biomarkers
R. Mignani (Rimini)

9.45 Discussion

10.00 PLENARY LECTURE
Cardiorenal Amyloidosis
C. Rapezzi (Bologna)
Introducing: C. Ronco (Vicenza)
TARRAGONA ROOM

IV SESSION

JOINT SESSION CARDIONEPHROLOGY STUDY GROUP - ITALIAN SOCIETY OF ARTIFICIAL NUTRITION

NUTRITIONAL AND METABOLIC FEATURES IN CARDIORENAAL PATIENTS
Chairmen: L. Gianotti (Monza), G. Iapichino (Milan)

8.30 Nutritional status evaluation in kidney disease patients
E. Giaquinto (Cesena)

8.50 Nutritional therapy in CKD patients
A. Cupisti (Pisa)

9.10 Kidney-Intestinal microbiota Axis
S. Riso (Vercelli)

9.30 Artificial nutrition in AKI patients
M. Zanello (Bologna)

9.50 Malnutrition and cardiorenal syndrome
D. Radrizzani (Legnano)

10.10 Obesity paradox and acute kidney failure
M. Zanetti (Trieste)

EXHIBIT HALL

10.30 Coffee Break with the Expert
**LEPTIS MAGNA 2-4 ROOM**

**V SESSION**

**ACUTE KIDNEY INJURY**

Chairmen: *P. Raggi* (Edmonton - Canada), *C. Ronco* (Vicenza)

**11.30**  
AKI: epidemiology and clinical features  
*C. Ronco* (Vicenza)

**11.45**  
AKI and heart failure  
*P. McCullough* (Dallas, Texas - USA)

**12.00**  
Cytokines removal and cardiac surgery  
*V. Cantaluppi* (Novara)

**12.15**  
AKI and sepsis  
*J. Kellum* (Philadelphia - USA)

**12.30**  
Endotoxins and type - 1 cardiorenal syndrome  
*M.G. Virzì* (Vicenza)

**12.45**  
Renal replacement treatments in AKI patients  
*C. Ronco* (Vicenza)

**13.00**  
Discussion

---

**LEPTIS MAGNA 1 ROOM**

**V SESSION**

**HEART FAILURE MANAGEMENT IN CARDIORENAL PATIENTS**

Chairmen: *E. Ferramosca* (Lecce), *A. Santoro* (Bologna)

**11.30**  
Diuretics, heart failure-related systemic congestion and Karl Popper’s turkey  
*G. Cice* (Naples)
11.45  Neprilisine inhibition in heart failure  
C. Parisi (Rome)

12.00  Guanylate cyclase stimulators and heart failure  
A. Fucili (Ferrara)

12.15  Therapeutic strategies for chronic hyperkalemia in heart failure patients  
A. Bellasi (Bergamo)

12.30  Intra and extracorporeal fluids balance in heart failure  
P. McCullough (Dallas, Texas - USA)

12.45  Extracorporeal’s fluids removal in patients affected by cardiorenal syndrome  
V. Panichi (Versilia)

13.00  Apheresis and cardio-renal syndrome  
A. Santoro (Bologna)

13.15  Discussion

TARRAGONA ROOM

V SESSION  
ACUTE CORONARY SYNDROME AND CHRONIC RENAL FAILURE  
Chairmen: G. Patti (Rome), A. Rubboli (Bologna)

11.30  Which does eGFR equation better predict outcome in patients with acute coronary syndrome?  
F. Floccari (Civitavecchia)

11.45  Patients with acute coronary syndrome and chronic renal failure: contemporary trends on early treatment strategies  
M. Tubaro (Rome)
12.00 Impact of chronic renal failure at early and one-year follow-up after acute coronary syndrome:
   a) The bleeding risk outweighs the ischemic risk!
      V. Pengo (Padua)
   b) The ischemic risk outweighs the bleeding risk!
      P. Calabrò (Naples)

12.30 Acute coronary syndrome and chronic renal failure: which data from real-world registries?
   a) ISAC Registry
      R. Bugiardini (Bologna)
   b) START ANTIPLATELET Registry
      R. Marcucci (Florence)

13.00 Long-term antithrombotic therapy in patients with chronic renal failure and previous acute coronary syndrome: new evidence
      G. Di Pasquale (Bologna)

13.15 Discussion

LEPTIS MAGNA 2-4 ROOM

LUNCHEON SYMPOSIUM
PERITONEAL DIALYSIS IN CARDIORENAL PATIENTS
Chairmen: C. Crepaldi (Vicenza), A.R. Rocca (Rome)

13.30 Clinical studies of PD in cardiorenal syndrome and heart failure
      A. Kazory (Gainsville - USA)

13.45 Fluids’ balance in peritoneal dialysis
      O. Heimburger (Stockholm - Sweden)

14.00 The pathophysiology of the cardiorenal syndrome and potential use of peritoneal ultrafiltration
      J. Bargman (Toronto - Canada)
**LEPTIS MAGNA 1 ROOM**

**LUNCHEON SYMPOSIUM**

**HEMODIALYSIS TREATMENTS AND CARDIORENAL PATIENTS**
Chairmen: *M. Morosetti* (Rome), *P. Trambaiolo* (Rome)

13.30 Immunoadsorption in heart transplant’s patients
*C. Maiello* (Naples)

13.50 Electrolytes’balance in Continuous Renal Replacement Therapy with citrate
*S. Morabito* (Rome)

14.10 Immunomodulation in septic patients
*G. Paternoster* (Potenza)

14.30 Discussion

**TARRAGONA ROOM**

**LUNCHEON SYMPOSIUM**

**HEART FAILURE: POTENTIAL APPROACHES FROM ACUTE TO CHRONIC SETTINGS**
Chairman: *E. Galli* (Treviglio), *V. La Milia* (Milan)

13.30 Continuous ultrafiltration and extracorporeal devices: techniques and outcomes
*V. Cantaluppi* (Novara)
13.50 Wearable device-based PUF (Peritoneal Ultrafiltration) 
TBA

14.10 Frequent hemodialysis in heart failure patients 
TBA

14.30 Discussion

CESAREA ROOM

13.30 LUNCHEON SYMPOSIUM 
TBA

LEPTIS MAGNA 2-4 ROOM

VI SESSION
RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS (RAASi) ENABLING THERAPIES AND CHRONIC HYPERKALEMIA MANAGEMENT
Chairmen: L. De Nicola (Naples), E. Paoletti (Genoa)

15.00 Epidemiology and diagnosis of chronic hyperkalemia 
L. De Nicola (Naples)

15.15 Chronic hyperkalemia risk factors 
E. Paoletti (Genoa)

15.30 RAAS inhibition and hyperkalemia 
G. Pajes (Albano Laziale)

15.45 Therapeutic strategies for chronic hyperkalemia:
   a) Dietetic interventions
      A. Cupisti (Pisa)
   b) Pharmacological options
      S. Bianchi (Livorno)

16.15 Discussion
LEPTIS MAGNA 1 ROOM

VI SESSION
AUTOSOMIC DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) AND CARDIO-RENAL INVOLVEMENT
Chairmen: M. Galliani (Rome), P. Peverini (Rieti)

15.00  ADPKD: an up to date
       L. Trepiccione (Naples)

15.15  Disease’s progression models:
       a) ERA-EDTA approach
             R. Torra (Barcelona - Spain)
       b) Italian approach
             F. Scolari (Brescia)

15.45  Imaging diagnosis in ADPKD patients
       A. Granata (Agrigento)

16.00  Therapeutic management of ADPKD patients: real world data
       and future perspectives
       R. Magistroni (Modena)

16.15  Patient’s interview
       F. Floccari (Civitavecchia)

TARRAGONA ROOM

VI SESSION
QUESTIONS’ CLINIC: CLINICAL CARDIONEPHROLOGY
Chairmen: A. Bellasi (Bergamo), R. Rivera (Desio)

EXHIBIT HALL

16.30  Coffee Break with the Expert
LEPTIS MAGNA 2-4 ROOM

VII SESSION
IRON DEFICIENCY, ANEMIA AND CARDIORENAL SYNDROME
Chairmen: M. Fusaro (Padua), R. Rivera (Desio)

17.30 Iron deficiency, anemia and heart failure: an up to date
P. Terrosu (Sassari)

17.50 Multidisciplinary Round Table
Internal Medicine point of view
D. Girelli (Verona)

Nephrologist’s point of view
R. Minutolo (Naples)

Cardiologist’s point of view
M. Senni (Bergamo)

18.50 Discussion

LEPTIS MAGNA 1 ROOM

VII SESSION
DIABETIC PATIENT WITH METABOLIC SYNDROME: REAL WORLD EVIDENCES
Chairmen: R. Addesse (Tivoli), V. Toscano (Rome)

17.30 Hypoglicemic, but non-insulinemic therapy, in CKD patients:
how collect safety and efficacy in every CKD stages
S. Settembrini (Naples)
17.50 New therapies for dyslipidemia management in cardiorenal patients: the role of fixed pharmacological association

TBA

18.10 Omega-3 fatty acids and cardiovascular damage’s prevention in CKD patients

A. De Pascalis (Lecce)

18.30 Statin therapy in dialysis patients: top or flop?

S. Andrulli (Lecco)

18.50 Discussion

TARRAGONA ROOM

VII SESSION

CARDIORENAL INVOLVEMENT IN SYSTEMIC VASCULITIS AND RARE DISEASES

Chairmen: V. Montinaro (Tricase), A. Pani (Cagliari)

17.30 Therapeutic perspectives in systemic vasculitis

S. Sciascia (Turin)

Discussant: A. Mitrotti (Bari)

17.50 Pathogenic classification of MGRS

A. Angioi (Cagliari)

Discussant: G. Piscopo (Bari)

18.10 Modulation of complement activation in atypical hemolytic uremic syndrome

G. Castellano (Bari)

Discussant: A. Atzeni (Cagliari)
18.30  Immunopathogenesis of idiopathic membranous nephropathy
M. Fiorentino (Bari)
Discussant: D. Santoro (Messina)

18.50  Discussion

19.00  Closing
VIII SESSION
FAST AND FURIOUS 1
CARDIORENAAL ARENA ON CKD-MBD
Chairman: F. Locatelli (Lecco)

8.30 **Burning questions 1**

The role of calcimimetic in CKD
D. Russo (Naples)

Cinacalcet or etelcalcetide? To whom?
A. Bellasi (Bergamo)

Surgical parathyroidectomy?
S. Mazzaferro (Rome)

**First round: wrap-up and take home messages**

9.00 **Burning questions 2**

Biomarkers: PTH and alkaline phosphatase
M.C. Mereu (Cagliari)

The role of bone biopsy
M. Fusaro (Padua)

Vascular calcification: does it matter?
P. Raggi (Edmonton)

**Second round: wrap-up and take home messages**
9.30 **Burning questions 3**

Bone fractures in CKD patients  
*M. Di Luca* (Pesaro)

Active or native Vitamin D?  
*M. Pasquali* (Rome)

New calcium free phosphate binders  
*M. Cozzolino* (Milan)

**Third round: wrap-up and take home messages**

10.00 Hypoparathyroidism and CKD  
*A. Sandonati* (Rome)

10.15 **PLENARY LECTURE**  
*Erythropoietin, chronic kidney disease and cardiovascular outcomes: a 30 years history*  
*R. Rivera* (Desio)  
Introducing: *A. De Pascalis* (Lecce)

---

**LEPTIS MAGNA 1 ROOM**

**VIII SESSION**  
**DIABETIC NEPHROPATHY 1**  
Chairmen: *A. Selvi* (Perugia), *V. Toscano* (Rome)

8.30 Novel association therapies for every step of treatment  
*R. Buzzetti* (Rome)

9.00 SGLT-2 inhibitors and cardiovascular outcomes: lessons from CVOTs and RWE studies  
*G. Pugliese* (Rome)
9.30 GLP-1 agonists’ impact on cardiovascular mortality and morbidity
S. Settembrini (Naples)

10.00 PLENARY LECTURE
New perspectives in the treatment of diabetic nephropathy
R. Minutolo (Naples)
Introducing: G. La Manna (Bologna)

TARRAGONA ROOM

VIII SESSION
CLINICAL NUTRITION IN NEPHROLOGY: ISSUES OF DAILY CLINICAL PRACTICE IN CKD

Relevant nutritional topics for CKD patients, caregivers and clinicians in Nephrology
Chairmen: V. Bellizzi (Salerno), G. Brunori (Trento)

8.30 Introduction
G. Brunori (Trento)

8.35 What the CKD patients ask to social media on nutritional treatment?
G. Quintaliani (Perugia)

8.50 Priorities on nutritional treatment in CKD according to stakeholders
V. Bellizzi (Salerno)

9.05 Discussion

Practical renal nutrition issues in the real life
Chairmen: V. Bellizzi (Salerno), B. Di Iorio (Avellino)

9.15 Low-proteins/high-carbohydrates or normal-proteins/low-carbohydrates diet in diabetic CKD patients?
D. Santoro (Messina)
9.30 Safety of very low-protein/vegetarian diets in CKD: iper-kalemia
B. Di Iorio (Avellino)

9.45 Salt intake and autosomal dominant polycystic kidney disease
F. Scolari (Brescia)

10.00 Dietary modulation of Gut Microbioma in CKD
E. Fiaccadori (Parma)

10.15 Advice or device to improve adherence to nutritional treatment in CKD?
C. D’Alessandro (Pisa)

10.30 Discussion

EXHIBIT HALL

10.45 Poster Session
Discussant: F.R. Festuccia (Rome), V. Pistolesi (Rome)

LEPTIS MAGNA 2-4 ROOM

IX SESSION
FAST AND FURIOUS 2
CARDIORENOAL ARENA ON ATRIAL FIBRILLATION IN CKD
Chairmen: F.R. Pugliese (Rome), F. Summaria (Rome)

11.15 Burning questions 1 - CKD and Heart Failur
Fast: Which DOAC should be used?
L. Di Lullo (Colleferro)
Furious: Please, do not use DOACs
G. Pulignano (Rome)
Neither “Fast” or “Furious”: Vitamin K antagonists and CKD: angel or devil?
A. Bellasi (Bergamo)

First round: wrap-up and take home messages

11.45 Burning questions 2 - The Real World
Fast: DOACs and CKD: from clinical trials to real world data
M. Uguccioni (Rome)
Furious: Frail and older patients with CKD: which DOAC?
A. Ungar (Florence)
Neither “Fast” or “Furious”: Thromboembolic and hemorrhagic risk score calculators in CKD
M. Ravera (Genoa)

Second round: wrap-up and take home messages

12.15 Burning questions 3 - CKD and atrial fibrillation in Emergency Department
Fast: An highway to cardioversion
C. Lavalle (Rome)
Furious: Pulmonary embolism prevention
M.P. Ruggieri (Rome)
Neither “Fast” or “Furious”: Deep venous thrombosis management
L. Zuccaro (Rome)

Third round: wrap-up and take home messages

13.00 Anticoagulant therapy and cardiovascular calcifications progression
A. De Vriese (Bruges - Belgium)
IX SESSION
DIABETIC NEPHROPATHY 2
Chairmen: G. Del Rosso (Teramo), E. Paoletti (Genoa)

11.15 Diabetic nephropathy and cardiovascular implications
M. Ravera (Genoa)

11.30 DPP-IV efficacy and safety in CKD patients:
new real world data
N. Napoli (Terracina)

11.45 Diabetic disease’s management in dialysis patients
O. Disoteo (Milan)

X SESSION
NEW TECHNOLOGIES IN CARDIONEPHROLOGY
Chairmen: N. Rifici (Latina), F. Tulli (Palestrina)

12.00 HFR and cardiovascular outcome
G. La Manna (Bologna)

12.15 Percutaneous coronary intervention in high-risk patients with
co-morbidities and multivessel coronary artery disease
V. Pasceri (Rome)

12.30 HFR and hepcidin removal
G. Donati (Bologna)

12.45 Progress in cardiac pacing: which role for the leadless devices?
N. Di Belardino (Anzio)

13.00 Discussion
IX SESSION
APHERESIS IN CARDIORENAL PATIENTS
Chairman: A. Santoro (Bologna)

11.15 Lipoprotein (a) – risk marker and therapeutic target
R. Klingel (Frankfurt - Germany)

11.30 Rheopheresis and microvascular complications in cardiorenal patients
A. Ramunni (Bari)

11.45 Discussion

X SESSION
INTERACTIVE TRAINING SESSION FOR DIETICIANS IN CARDIO-NEPHRO-DIABETOLOGY

LEPTIS MAGNA 2-4 ROOM

XI SESSION
CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH HEMODIALYSIS VASCULAR ACCESS
Chairmen: M. Gallieni (Milan), M. Tozzi (Varese)

13.20 The impact of haemodialysis arteriovenous fistula on haemodynamic parameters of the cardiovascular system
J. Malik (Ljubljana - Slovenia)

13.40 Cardiovascular disease and HD: cvc trigger or destiny
C. Lomonte (Aquaviva delle Fonti)

13.55 Cardiac implantable electronic device and vascular access: Strategies to overcome problems
F. Caravati (Varese)
14.10 High-range FAV and theft syndromes: possible strategies
*N. Pirozzi* (Rome)

14.25 Graft for low flow VA: an option for patients with heart failure
*M. Tozzi* (Varese)

14.40 Radiological intervention in high flow access
*P. Quaretti* (Pavia)

14.55 Discussion

---

**LEPTIS MAGNA 1 ROOM**

**XI SESSION**

**NURSES AND CLINICIANS INTERACTIVE SESSION ON CARDIONEPHROLOGY**

Chairmen: *R. Mari* (Colleferro), *U. Tulli* (Tivoli)

CRRT and nurses. Learning to the job—Dowtime
*P. Martucci* (Rome)

Central Venous Catheters: guidelines, bundle and best practice
*A. Fontana* (Tivoli)

CKD patients’ fluids and electrolytes management in Intensive Care Units
*S. Accardo* (Rome)

CRRT and available anticoagulation strategies: which is the best one?
*TBA*

15.00 **CLOSING REMARKS**

**FAREWELL PARTY**
EDUCATIONAL COURSES
Educational Courses will take place on Tuesday, March 12th from 9.00 to 13.00. Participation at the courses is free, but a pre-registration is required.

E-POSTER
During the Congress, a Poster Session will take place on Thursday, March 14th from 10.45 until 11.45
Scientific works must be sent by January 15th, 2019 through the website [https://fenicia-events.eu/cardionefro/call-for-abstract/](https://fenicia-events.eu/cardionefro/call-for-abstract/)
All the abstracts must be received exclusively in electronic and in English, completing the special form. The first Author will be considered as the one who will make the presentation and must be regularly registered at the Congress; Authors under 35 will be entitled to free admission to the Congress.

PUBLICATION OF ABSTRACT
All the abstracts received will be published on the website [www.feniciaevents.eu/cardionefro](http://www.feniciaevents.eu/cardionefro), and three best abstracts will be published in the Cardionefro Magazine

CME
For the Italian Participants: Cardionephrology 2019 will participate at the Continuing Medical Education

SCIENTIFIC TECHNICAL EXHIBITION
During the Congress an exhibition will be set up for biomedical, pharmaceutical and scientific publishing industry
- Tuesday, March 12th 9.00-20.00
- Wednesday, March 13th 8.30-19.00
- Thursday, March 14th 8.30-14.30
ORGANIZING SECRETARY ON SITE
Organizing Secretariat in the Congress Venue will observe the following timetable:
• Monday, March 11th (only for Delegations and Companies) 9.00-19.00
• Tuesday March 12th 8.00-20.00
• Wednesday March 13th 8.00-19.30
• Thursday March 14th 8.00-15.00
GENERAL INFORMATION

VENUE
ERGIFE PALACE HOTEL Largo Lorenzo Mossa
For information and hotel reservations please contact the Organizing Secretariat:
FENICIA EVENTS & COMMUNICATION
Phone: +39 06 87671411 - Fax: +39 06 62278787
Cardioneuro2019@fenicia-events.eu;
https://fenicia-events.eu/cardioneuro

REGISTRATION
Congress website https://feniciaevents.eu/cardioneuro/iscrizioni/

REGISTRATION FEES (rates include VAT 22%)

<table>
<thead>
<tr>
<th>Category</th>
<th>By December 31st 2018</th>
<th>After that date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doctors</td>
<td>€ 122,00</td>
<td>€ 183,00</td>
</tr>
<tr>
<td>Nurses/Dietitians</td>
<td>€ 61,00</td>
<td>€ 91,50</td>
</tr>
<tr>
<td>* Postgraduate</td>
<td>€ 61,00</td>
<td>€ 91,50</td>
</tr>
<tr>
<td>* Students</td>
<td>free of charge</td>
<td>free of charge</td>
</tr>
</tbody>
</table>

* Each student and trainees must submit a copy of the certificate of registration at Specialities School.

Registration fee includes: participation in all scientific sessions, coffee breaks and light lunch, farewell party, certificate of attendance, badge and congress bag.

BADGE AND CERTIFICATE OF PARTICIPATION
Badge and the certificate of attendance can be printed by all the participants at the desks prepared using their QRCode received by e-mail when registering for the event.

CANCELLATIONS AND REFUNDS
Any refund will be recognized
**OFFICIAL LANGUAGES OF THE CONGRESS**
English and Italian.
Translation tool will be available in the following rooms:
Leptis Magna 2-4
Leptis Magna 1
Tarragona

**HOW TO REACH THE VENUE**
Hotel Ergife Palace is located about 200 meters from Via Aurelia, just 4 km from Grande Raccordo Anulare and 26 km from Fiumicino airport. The major points of cultural and commercial importance of the city are easily reachable with the bus lines and the underground that allow the connection.

**PUBLIC TRANSPORTATION** Hotel is easily reachable by public transport, especially for those arriving from Termini station or from the center of Rome using the underground line A and getting off at Cornelia, then about 1.200 meters, about 15 minutes to walk or bus 246. 2 stops (get off at the Pio IX clinic) leaving from Piazza Irnerio. **BY TRAIN** From Termini Station take the underground line A towards Battistini and get off at Cornelia. Then take the line 246 towards Malagrotta and get off after 3 stops.

**BY PLANE** From Fiumicino airport: Leonardo Da Vinci airport is about 25 km from the hotel. A direct train (Leonardo Express) leaves the airport every 30 minutes and connects Fiumicino to Roma Termini. Once in Termini take the metro line A direction Battistini, stop Cornelia. From Cornelia take bus 246 for three stops. The hotel is just a few steps from the stop.

From Ciampino airport: Ciampino airport is about 30 km from Ergife Palace Hotel. With Terravision bus you can easily reach the Termini station. From Termini it is possible to 29 reach the hotel by taxi or by taking the metro line A direction Battistini. From Ciampino to the hotel by taxi the ride lasts about 40 minutes and costs about 50.00. You can also reach Termini by bus CO.TRA.L. Once to Termini take the metro line A direction Battistini, get off Cornelia. Da Cornelia take the bus 246 for three stops. The hotel is a few steps from the bus stop.

**BY CAR** At the exit of the motorway take the Grande Raccordo Anulare towards Fiumicino exit n.1. Direction Aurelia-Città del Vaticano. After about...
3 Km at the fourth traffic light turn right into Via Lombardi. The hotel is at the bottom of the Street.

**PARKING**
The Hotel has a parking for 800 paid parking spaces (€ 15,00 per day).